Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study

Keyphrases

• Long-term Treatment 100%
• Sulfonylurea 100%
• KCNJ11 Gene 100%
• International Cohort 100%
• Neonatal Diabetes 100%
• Permanent Neonatal Diabetes 41%
• Hemoglobin A1c (HbA1c) 33%
• Glycemic Control 33%
• KCNJ11 33%
• Insulin 25%
• Sulfonylurea Therapy 25%
• Norway 16%
• Regional Health Authorities 16%
• Severe Hypoglycemia 16%
• Sulfonylurea Failure 16%
• Italy 8%
• Vascular Complications 8%
• High Dose 8%
• Same Patient 8%
• Appropriate Treatment 8%
• Francophone 8%
• Type 2 Diabetes Mellitus (T2DM) 8%
• Metabolic Control 8%
• Clinical Characteristics 8%
• Diabetes 8%
• Follow-up Interval 8%
• Rome 8%
• Channel Activation 8%
• Long-term Efficacy 8%
• Paired Data 8%
• Ministry of Health 8%
• Reintroduction 8%
• Long-term Safety 8%
• Poland 8%
• Slovak 8%
• Highly Effective 8%
• Development Agencies 8%
• Diabetes Complications 8%
• Neurological Features 8%
• ATP-sensitive Potassium Channel 8%
• European Regional Development Fund 8%
• No-report 8%
• Paris France 8%
• Diabetes UK 8%
• Operational Program 8%
• Research Councils 8%
• Bergen 8%
• Royal Society 8%
• Insulin Control 8%
• Research Agencies 8%
• Annual Data 8%
• Jebsen 8%
• Jeunes 8%
• Western Norway 8%
• Development Research 8%
• Aides 8%
• Wellcome Trust 8%
• Exeter 8%
• European Research Council 8%
• Octamer-binding Transcription Factor 4 (OCT4) 8%

Medicine and Dentistry

• Diabetes 100%
• Cohort Analysis 100%
• Sulfonylurea 100%
• Glycemic Control 23%
• Side Effect 11%
• Hypoglycemia 11%
• Drug Megadose 5%
• Maturity Onset Diabetes of the Young 5%
• Clinician 5%
• Metabolic Regulation 5%
• Adenosine Triphosphate Sensitive Potassium Channel 5%
• Diabetes UK 5%
• Microvascular Complication 5%
• Complications of Diabetes Mellitus 5%